Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) is crucial for neuronal development and implicated in neurodegenerative diseases like Alzheimer's and Down syndrome.
• DYRK1A's role in cell cycle regulation also suggests potential in oncologic indications, and its inhibition is explored for diabetes treatment.

Purpose of the Study:

• To discover and optimize novel inhibitors of DYRK1A.
• To develop a lead series of compounds with potential therapeutic applications in various diseases.

Main Methods:

• Structure-activity relationship (SAR) analysis was employed to guide inhibitor design.
• High-resolution X-ray crystallography was used to understand inhibitor-target interactions.
• Physicochemical properties, selectivity, permeability, and P-glycoprotein liability were assessed.

Main Results:

• A series of pyrazolo[1,5-b]pyridazine derivatives were identified as potent DYRK1A inhibitors.
• These compounds demonstrated excellent ligand efficiencies, favorable physicochemical properties, and high selectivity across the kinome.
• Compound 11 showed good cellular activity, permeability, and no P-glycoprotein liability, indicating in vivo potential.

Conclusions:

• The pyrazolo[1,5-b]pyridazine scaffold represents a viable lead series for developing new therapeutics targeting DYRK1A.
• These findings support the therapeutic potential of DYRK1A inhibition in neurodegenerative diseases, diabetes, and cancer.